Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms.

Muscle & nerve·2026
Same author

Positive allosteric modulator selective for adult muscle nicotinic acetylcholine receptor.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Brain : a journal of neurology·2026
Same author

Prevalence and Geographical Distribution of Patients With Congenital Myasthenic Syndromes in the United Kingdom.

Muscle & nerve·2025
Same author

Myasthenic syndromes: mistaking genetic for acquired.

Practical neurology·2025
Same author

Structures of the human adult muscle-type nicotinic receptor in resting and desensitized states.

Cell reports·2025

Related Experiment Video

Updated: May 15, 2026

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Synaptic dysfunction in congenital myasthenic syndromes.

David Beeson1

  • 1Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom. David.Beeson@ndcn.ox.ac.uk

Annals of the New York Academy of Sciences
|January 3, 2013
PubMed
Summary

Congenital myasthenic syndromes (CMS) are genetic neuromuscular disorders. Improved diagnostics reveal diverse mutations, necessitating tailored treatments based on identified molecular mechanisms for better patient outcomes.

More Related Videos

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Related Experiment Videos

Last Updated: May 15, 2026

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Congenital myasthenic syndromes (CMS) are inherited neuromuscular junction disorders causing muscle weakness.
  • Increasingly recognized cases are linked to over 300 identified mutations across numerous genes.
  • Genetic defects in CMS present diverse phenotypes, impacting treatment strategies.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying various CMS-causing mutations.
  • To correlate specific pathogenic mechanisms with clinical phenotypes for personalized treatment.
  • To introduce novel methods for identifying gene mutations and assessing variant pathogenicity.

Main Methods:

  • Analysis of DNA sequence variants, exemplified by DOK7 gene variants.
  • Investigation of acetylcholine receptor (AChR) ɛ-subunit mutations affecting ion channel function.
  • Development and application of new gene mutation identification techniques.

Main Results:

  • Demonstrated methods for determining the pathogenicity of DNA sequence variants.
  • Identified a novel mechanism of AChR dysfunction due to reduced ion channel conductance.
  • Cataloged over 300 distinct mutations in more than 350 unrelated families.

Conclusions:

  • Understanding molecular mechanisms is crucial for tailoring CMS treatments.
  • The study provides insights into diverse molecular pathways of synaptic dysfunction.
  • Advanced diagnostic methods are improving the recognition and characterization of CMS.